Antibiotic Spring? Regulatory Incentives Spur Activity – And Maybe Medical Advances

Achaogen Inc.'s plazomicin, which recently became the first novel systemic antibiotic candidate designated a breakthrough therapy by FDA, is at the forefront of what could be a small wave of new antibacterials that offer improvements in efficacy over existing products.

Despite many and varied global efforts to revitalize antibiotics R&D in the face of growing antimicrobial resistance, new antibiotics in the US for the past decade have at best offered incremental advances